Insider Buying: Cytosorbents Co. (NASDAQ:CTSO) CFO Acquires 11,363 Shares of Stock

Cytosorbents Co. (NASDAQ:CTSO) CFO Peter J. Mariani purchased 11,363 shares of Cytosorbents stock in a transaction that occurred on Wednesday, December 11th. The shares were purchased at an average cost of $0.89 per share, with a total value of $10,113.07. Following the transaction, the chief financial officer now directly owns 361,363 shares of the company’s stock, valued at $321,613.07. This represents a 3.25 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Cytosorbents Stock Up 1.0 %

Shares of NASDAQ:CTSO traded up $0.01 during mid-day trading on Friday, reaching $0.90. 53,071 shares of the company traded hands, compared to its average volume of 124,414. Cytosorbents Co. has a 52 week low of $0.70 and a 52 week high of $2.15. The company’s 50 day moving average price is $0.98 and its 200-day moving average price is $1.01. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06.

Analysts Set New Price Targets

CTSO has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a research report on Monday, November 11th. StockNews.com initiated coverage on shares of Cytosorbents in a report on Thursday. They set a “hold” rating for the company.

Institutional Trading of Cytosorbents

Institutional investors and hedge funds have recently modified their holdings of the company. Atomi Financial Group Inc. purchased a new stake in shares of Cytosorbents during the third quarter worth about $51,000. CM Management LLC grew its holdings in shares of Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after purchasing an additional 25,000 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares during the last quarter. Finally, Sargent Investment Group LLC increased its stake in Cytosorbents by 4.9% during the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after acquiring an additional 67,181 shares during the last quarter. 32.87% of the stock is currently owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.